Leading Product Revenue

May 08, 2025

(¥ million)

Brand name /Code No.	Active Ingredient	Indications	Launch Date	Sales 2023 (IFRS)	Sales 2024 (IFRS)	Sales 2025 (IFRS) (estimated)
Brand name /Code No.	Active Ingredient	Indications	Launch Date	Sales 2023 (IFRS)	Sales 2024 (IFRS)	Apr-Sep	Annual
Viltepso				17,530	21,782	10,800	21,500
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(2,400)	(4,800)
(U.S.)				(13,123)	(17,117)	(8,400)	(16,700)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	8,300	16,800
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	3,500	7,300
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	1,700	3,100
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	2,600	5,200
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,000	2,000
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,250	2,500
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	1,200	2,500
Fintepla	fenfluramine hydrochloride	Dravet syndrome Lennox-Gastaut syndrome	Apr-2014	377	2,067	1,700	4,000
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	7,300
Profit in co-promotion				8,658	9,170	4,700	9,600
Revenues from the licensing of industrial property rights				40,304	45,585	22,800	47,500
Pharmaceuticals				125,105	138,654	71,000	150,000
Functional Food				23,150	21,577	10,500	23,000
Revenue				148,255	160,232	81,500	173,000

Brand name /Code No.	Active Ingredient	Indications	Launch Date	Sales 2023 (IFRS)	Sales 2024 (IFRS)	Sales 2025 (IFRS) (estimated)
Brand name /Code No.	Active Ingredient	Indications	Launch Date	Sales 2023 (IFRS)	Sales 2024 (IFRS)	Apr-Sep	Annual
Viltepso				17,530	21,782	10,800	21,500
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(2,400)	(4,800)
(U.S.)				(13,123)	(17,117)	(8,400)	(16,700)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	8,300	16,800
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	3,500	7,300
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	1,700	3,100
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	2,600	5,200
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,000	2,000
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,250	2,500
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	1,200	2,500
Fintepla	fenfluramine hydrochloride	Dravet syndrome Lennox-Gastaut syndrome	Apr-2014	377	2,067	1,700	4,000
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	7,300
Profit in co-promotion				8,658	9,170	4,700	9,600
Revenues from the licensing of industrial property rights				40,304	45,585	22,800	47,500
Pharmaceuticals				125,105	138,654	71,000	150,000
Functional Food				23,150	21,577	10,500	23,000
Revenue				148,255	160,232	81,500	173,000

Back Number

Related Link

Nippon Shinyaku’s DNA

Research & Development

Business/Financial Information